← All trials
NCT07142707
Phase 1Interventional
Includes initial studies to determine the metabolism and pharmacologic actions of drugs in humans, the side effects associated with increasing doses, and to gain early evidence of effectiveness; may include healthy participants and/or patients.
View on ClinicalTrials.gov ↗Timeline
- Start date
- Sep 3, 2025
- Primary completion
- May 30, 2026
- Completion date
- May 30, 2026
- First posted
- Aug 27, 2025
- Last posted
- Sep 9, 2025
- Enrollment
- 64
- Arms / groups
- 3 / —
- Source
- AACT · ctgov ingestion
Sponsors
- MBX BiosciencesLead sponsor
Drugs studied
Indications studied
CDEK-curated fields only — the ClinicalTrials.gov results mirror (baseline measures, adverse events, participant flow) is a separate, currently-dormant pipeline; see MIGRATION_PLAN.md.